Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation.
COVID-19
SARS-CoV-2
blood
mass spectrometry
plasma
proteomics
severe
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
10 Feb 2023
10 Feb 2023
Historique:
received:
31
12
2022
revised:
26
01
2023
accepted:
06
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection leads to a wide range of clinical manifestations and determines the need for personalized and precision medicine. To better understand the biological determinants of this heterogeneity, we explored the plasma proteome of 43 COVID-19 patients with different outcomes by an untargeted liquid chromatography-mass spectrometry approach. The comparison between asymptomatic or pauci-symptomatic subjects (MILDs), and hospitalised patients in need of oxygen support therapy (SEVEREs) highlighted 29 proteins emerged as differentially expressed: 12 overexpressed in MILDs and 17 in SEVEREs. Moreover, a supervised analysis based on a decision-tree recognised three proteins (Fetuin-A, Ig lambda-2chain-C-region, Vitronectin) that are able to robustly discriminate between the two classes independently from the infection stage. In silico functional annotation of the 29 deregulated proteins pinpointed several functions possibly related to the severity; no pathway was associated exclusively to MILDs, while several only to SEVEREs, and some associated to both MILDs and SEVEREs; SARS-CoV-2 signalling pathway was significantly enriched by proteins up-expressed in SEVEREs (
Identifiants
pubmed: 36834989
pii: ijms24043570
doi: 10.3390/ijms24043570
pmc: PMC9962231
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : FAR 2017-2021
ID : FAR 2017-2021
Organisme : Fondazione Gigi & Pupa Ferrari Onlus
ID : Pupa Ferrari Onlus
Organisme : Regione Lombardia, regional law n° 9/2020, resolution n° 3776/2020": Programma degli interventi per la ripresa economica: sviluppo di nuovi accordi di collaborazione con le università per la Ricerca, l'Innovazione e il Trasferimento tecnologico: NephropaT
ID : regional law n° 9/2020, resolution n° 3776/2020"
Organisme : Regione Lombardia POR FESR 2014-2020. Misura a sostegno dello sviluppo di collaborazioni per l'identificazione di terapie e sistemi di diagnostica, protezione e analisi per contrastare l'emergenza Coronavirus e altre emergenze virali del futuro: Caratteri
ID : POR FESR 2014-2020
Références
Proteomics Clin Appl. 2022 Oct 11;:e2200070
pubmed: 36217943
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Gut. 2021 Nov;70(11):2096-2104
pubmed: 34489306
J Pharmacol Sci. 2022 Sep;150(1):9-20
pubmed: 35926948
Life Sci Alliance. 2021 Jul 5;4(9):
pubmed: 34226277
Nat Rev Immunol. 2021 Apr;21(4):245-256
pubmed: 33723416
Viruses. 2021 Dec 24;14(1):
pubmed: 35062233
Oxid Med Cell Longev. 2022 May 9;2022:4526022
pubmed: 35557984
Cell. 2020 Jul 9;182(1):59-72.e15
pubmed: 32492406
Cell Syst. 2021 Jan 20;12(1):23-40.e7
pubmed: 33096026
Nat Commun. 2021 Jul 27;12(1):4543
pubmed: 34315889
Pathogens. 2021 Mar 19;10(3):
pubmed: 33808640
Genes Genomics. 2022 Dec 27;:
pubmed: 36574143
EBioMedicine. 2022 Nov;85:104293
pubmed: 36182629
Eur J Med Genet. 2021 Jun;64(6):104227
pubmed: 33872774
Int J Mol Sci. 2022 Feb 22;23(5):
pubmed: 35269564
Sci Rep. 2021 Mar 18;11(1):6357
pubmed: 33737684
Respir Med. 2021 Apr-May;180:106356
pubmed: 33713961
Nat Commun. 2021 Feb 17;12(1):1079
pubmed: 33597532
JCI Insight. 2020 Aug 6;5(15):
pubmed: 32554923
Biomolecules. 2021 Sep 28;11(10):
pubmed: 34680053
Clin Proteomics. 2022 Nov 8;19(1):38
pubmed: 36348270
Respir Res. 2022 Dec 13;23(1):343
pubmed: 36514048
J Biol Chem. 1992 Feb 5;267(4):2264-8
pubmed: 1370815
Front Genet. 2022 Aug 05;13:929887
pubmed: 35991542
PLoS One. 2022 Oct 7;17(10):e0268592
pubmed: 36206263
J Infect Dis. 2019 Sep 26;220(9):1498-1502
pubmed: 31287867
mBio. 2021 Apr 20;12(2):
pubmed: 33879594
PLoS One. 2022 Oct 21;17(10):e0276460
pubmed: 36269754
Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198
pubmed: 31066453
Proteomics. 2021 Jun;21(11-12):e2000278
pubmed: 33945677
Clin Transl Med. 2022 Jan;12(1):e704
pubmed: 35075803
Signal Transduct Target Ther. 2021 Sep 22;6(1):345
pubmed: 34552055
Acta Med Okayama. 2019 Oct;73(5):379-382
pubmed: 31649362
Signal Transduct Target Ther. 2021 Jun 3;6(1):216
pubmed: 34083512
J Proteomics. 2017 Feb 5;153:30-43
pubmed: 27542507
BMC Anesthesiol. 2022 Jul 20;22(1):232
pubmed: 35858852
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Crit Care Explor. 2022 Dec 01;4(12):e0800
pubmed: 36479446
Immunity. 2022 Dec 13;55(12):2436-2453.e5
pubmed: 36462503
Intern Med. 2007;46(20):1685-91
pubmed: 17938521
Front Immunol. 2021 Oct 13;12:738073
pubmed: 34721400
J Clin Invest. 1979 Oct;64(4):1118-29
pubmed: 90057
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
COPD. 2013 Feb;10(1):28-34
pubmed: 23272665
Nat Commun. 2022 Dec 15;13(1):7775
pubmed: 36522333
Virus Res. 2023 Jan 15;324:199024
pubmed: 36526016
Front Immunol. 2022 Sep 06;13:1011084
pubmed: 36148234
Front Immunol. 2021 Feb 11;11:604759
pubmed: 33643292
Cell Syst. 2020 Jul 22;11(1):11-24.e4
pubmed: 32619549
Int J Mol Sci. 2022 Sep 26;23(19):
pubmed: 36232655
J Med Virol. 2020 Oct;92(10):2036-2041
pubmed: 32347972
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Sci Rep. 2020 Dec 29;10(1):22418
pubmed: 33376242
Nihon Yakurigaku Zasshi. 2022;157(6):422-425
pubmed: 36328552
Rheumatol Int. 2022 Feb;42(2):273-277
pubmed: 34240250
Signal Transduct Target Ther. 2020 Aug 14;5(1):156
pubmed: 32796814